Micro-Ultrasound for Easier Prostate Cancer Screening
Dr. Laurence Klotz discusses micro-ultrasound as a faster, less invasive, more cost-effective screening strategy compared to mpMRI in this podcast.
This is Episode 1 of the Diagnostic Imaging podcast: The Reading Room. To subscribe, click here.
High-resolution micro-ultrasound does a better job of pinpointing clinically significant prostate cancer than MRI, said industry experts, and it can do so in a less expensive, simpler way.
According to an article published in the Canadian Urological Association Journal, micro-ultrasound is more sensitive to these types of cancers, functioning as a single-session option for prostate screening and targeted biopsy.
“High-resolution micro-ultrasound has the capability of imaging prostate cancer based on detecting alterations in ductal anatomy, analogous to multiparametric magnetic resonance imaging (mpMRI),” said lead study author Laurence Klotz, M.D., chair of prostate cancer research at Sunnybrook Hospital in Toronto, Canada. “This technology has the potential advantages of relatively low cost, simplicity, and accessibility compared to mpMRI.”
In this study, the team evaluated images from 1,040 men from 11 sites in seven countries who previously underwent mpMRI and also micro-ultrasound-guided biopsy. These biopsies were captured from both mpMRI targets with a PI-RADS score of >3 and micro-ultrasound targets with a PRIMUS >3.
According to their analysis, 39.5 percent of men were diagnosed with clinically significant prostate cancer, meaning they had a Gleason grade group of greater than or equal to 2. For micro-ultrasound and mpMRI, sensitivity was 94 percent and 90 percent, respectively, and their negative predictive value was 85 percent and 77 percent, respectively. Both strategies had 22-percent specificity, and their positive predictive values were similar – 44 percent and 43 percent, respectively.
Given the higher sensitivity for clinically significant prostate cancer compared to mpMRI and its lower cost and single-session option for prostate screening and targeted biopsy, micro-ultrasound could be an attractive imaging strategy for some patients.
In this podcast, Klotz discussed the use of micro-ultrasound in detecting prostate cancer and the role it could play in supplementing multi-parametric MRI in searching for and more easily identifying the disease.
New bpMRI Study Suggests AI Offers Comparable Results to Radiologists for PCa Detection
April 15th 2025Demonstrating no significant difference with radiologist detection of clinically significant prostate cancer (csPCa), a biparametric MRI-based AI model provided an 88.4 percent sensitivity rate in a recent study.
The Reading Room Podcast: Current Perspectives on the Updated Appropriate Use Criteria for Brain PET
March 18th 2025In a new podcast, Satoshi Minoshima, M.D., Ph.D., and James Williams, Ph.D., share their insights on the recently updated appropriate use criteria for amyloid PET and tau PET in patients with mild cognitive impairment.
Could Ultrafast MRI Enhance Detection of Malignant Foci for Breast Cancer?
April 10th 2025In a new study involving over 120 women, nearly two-thirds of whom had a family history of breast cancer, ultrafast MRI findings revealed a 5 percent increase in malignancy risk for each second increase in the difference between lesion and background parenchymal enhancement (BPE) time to enhancement (TTE).
MRI Study Suggests Shape of White Matter Hyperintensities May Be Predictive of Cognitive Decline
April 7th 2025Emerging research demonstrated that cognitive declines in memory, executive function and processing speed domains were associated with irregular shape of periventricular/confluent white matter hyperintensities.
What New Research Reveals About Novice Use of AI-Guided Cardiac Ultrasound
April 4th 2025In a study recently presented at the American College of Cardiology (ACC) conference, researchers found that novice use of AI-guided cardiac ultrasound after an AI-enabled electrocardiogram increased the positive predictive value for reduced left ventricular ejection fraction (LVEF) or aortic valve stenosis by 33 percent.
